Abstract
With an estimated prevalence of ≈25% in Western and Asian countries, non alcoholic fatty liver disease (NAFLD), caused by chronic excessive caloric intake, is the emerging as the most prevalent liver disorder worldwide. NAFLD exists in two clinical entities, non-alcoholic fatty liver disease (NAFL), a relative benign disease that carry on minimal risk of liver-related morbidity but significant risk of cardiovascular complications, and non-alcoholic steatohepatitis (NASH), a progressive liver disorder with a significant risk for development of liver-related morbidities and mortality. While, liver injury in NASH is contributed by lipid overload in hepatocytes, lipotoxicity, the main determinant of disease progression is an inflammation-driven fibrotic response. Here, we review the landscape of emerging pharmacological interventions in the treatment of NAFL and NASH. A consensus exists that, while treating the liver component of NASH requires development of novel pharmacological approaches, the future therapy of NASH needs to be tailored to the single patient and most likely will be a combination of agents acting on specific pathogenic mechanisms at different disease stage.
Citations
Nov 10, 2018·Expert Opinion on Pharmacotherapy·Yuji OgawaAtsushi Nakajima
Nov 13, 2018·Transplantation·Ivan LinaresMarkus Selzner
Jun 20, 2020·Expert Opinion on Investigational Drugs·Stefano FiorucciEleonora Distrutti
Mar 11, 2019·Lipids in Health and Disease·Qun LiuShi-Ying Xuan
May 24, 2019·Nutrients·Adriana CarinoStefano Fiorucci
Aug 10, 2019·Nutrients·Michele BiagioliStefano Fiorucci
Jan 10, 2020·Journal of Clinical and Translational Hepatology·Hui GaoShiying Xuan
Mar 5, 2019·Metabolomics : Official Journal of the Metabolomic Society·Da Jung KimJoo-Youn Cho
Oct 23, 2019·International Journal of Molecular Medicine·Xiu-Mei WangChang-Ping Li
Jun 10, 2020·JGH Open : an Open Access Journal of Gastroenterology and Hepatology·Micah Grubert Van IderstineGerald Y Minuk
May 20, 2020·Frontiers in Pharmacology·Lingyun XiaoXiaobin Zeng
Mar 29, 2020·Frontiers in Physiology·Hao-Ran DingHao-Zhen Ren
Jun 27, 2019·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Ruth C R MeexLuc J C van Loon
Jul 14, 2020·Frontiers in Cellular Neuroscience·Xiuping LiMinshu Li
Apr 4, 2019·International Journal of Molecular Medicine·Yulei LuChun Yang
Jul 25, 2019·Journal of Clinical Medicine·Peiling Tsou, Chang-Jiun Wu
Nov 25, 2019·Internal Medicine Journal·Tony Dazhong HuangAmany Zekry
Jan 6, 2021·Drugs·Daniel Sepulveda-CrespoIsidoro Martinez
Jul 22, 2019·Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids·Adriana CarinoStefano Fiorucci
Dec 29, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Adriana CarinoStefano Fiorucci
Jan 19, 2021·BioMed Research International·Tao HuangDalei Zhang
Feb 27, 2021·BMC Gastroenterology·Qing ZhangKuirong Lv
Feb 27, 2021·Progress in Lipid Research·Stefano FiorucciMichele Biagioli
Jun 12, 2020·Cellular and Molecular Gastroenterology and Hepatology·Trenton T RossWilliam P Esler
Jan 19, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Waleska Dornas, Vincent Lagente
Apr 27, 2021·Bioorganic Chemistry·Marianna PotenzaGiuseppe Bifulco
Oct 13, 2021·Nature Medicine·Roberto A CalleWilliam P Esler
Dec 5, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Silvia MarchianòStefano Fiorucci